CA-PONY.AI
7.3.2024 08:55:29 CET | Business Wire | Press release
Pony.ai, a leading global autonomous mobility company, held a Memorandum of Understanding (MoU) signing ceremony today with the Government of the Grand Duchy of Luxembourg (“The Government”) to advance the development of autonomous mobility in Luxembourg. The MoU was signed by Pony.ai Co-Founder and CEO Dr. James Peng and Luxembourg’s Minister of the Economy Lex Delles. This MoU represents a collaborative partnership between Luxembourg and Pony.ai, with the objective of fostering the research, development, and deployment of autonomous vehicles in Luxembourg.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240306928526/en/
Delegation from the Government of the Grand Duchy of Luxembourg visits Pony.ai’s office in Fremont, California, March 6, 2024 (Photo: Business Wire)
As a global leader in innovation and technology, Luxembourg presents an excellent opportunity for Pony.ai to further develop its leading autonomous mobility technology in Europe. Pony.ai, with the support of Luxinnovation and local stakeholders, intends to set up a regional hub in Luxembourg, which will serve as a center for Pony.ai’s cutting-edge research and development of autonomous vehicle technology. Pony.ai’s Luxembourg-based hub will be pivotal in driving technological advancements and tailoring solutions for the European market. In addition, the Government and Pony.ai aim to develop a robust local network to support operational capabilities in Luxembourg. Pony.ai looks forward to building strong local partnerships to support this effort.
Pony.ai co-founder and CEO Dr. James Peng said: “As a leading global autonomous vehicle company, Pony.ai is delighted to partner with Luxembourg as we continue our global expansion. We aim to bring to this partnership our cutting-edge AV technology, comprehensive training programs, and a commitment to establish a regional hub in Luxembourg as we continue our global expansion.”
Luxembourg Minister of the Economy Lex Delles said: “The intelligent mobility sector is one of our priorities with regard to the diversification of Luxembourg’s economy. Our aim is to make the Grand Duchy a pioneer in the field of autonomous driving on a European scale. As such, I am very pleased with the signature of an MoU with Pony.ai, a leader in autonomous mobility technologies and services. The signature today formalizes our collaboration and is an important step towards creating a synergy between the technical expertise of Pony.ai and the Luxembourg government's political strategy. The latter aims to promote research and technological development, job creation and sustainable economic growth.”
Pony.ai is a leader in autonomous mobility and in the commercialization of autonomous driving, operating Robotaxi, Robotruck and Personally Owned Vehicle (POV) business units, developing the safest autonomous driving capabilities on a global scale. Pony.ai is excited to continue its expansion into Luxembourg and the European market. For the past year, Pony.ai has engaged in detailed conversations surrounding robotaxi deployment use cases and opportunities with local stakeholders in Luxembourg and believes the country is an exciting and innovative region to introduce Pony.ai’s leading autonomous vehicles.
About Pony.ai
Leading global autonomous driving company Pony.ai, Inc. (“Pony.ai”) is pursuing an ambitious vision for autonomous mobility. We aim to bring safe, sustainable, and accessible mobility to the entire world. We believe that autonomous technology can make our roads exponentially safer for travelers. Founded in late 2016, Pony.ai has been a pioneer in extending autonomous mobility technologies and services at a rapidly expanding footprint of sites around the world. Pony.ai has formed partnerships with leading OEMs, including Toyota, SAIC, SANY, FAW Group, GAC Group, etc. To date, Pony.ai has driven over 30 million autonomous testing and operation kilometers (over 18.6 million miles) on open roads worldwide.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306928526/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Align Partners Issues Public Shareholder Letter and Submits Formal Shareholder Proposals to DB Insurance9.2.2026 15:26:00 CET | Press release
Align Partners underscores DBI’s persistent undervaluation (0.40x Adjusted PBR), despite industry-leading profitability, identifying inefficient capital allocation and governance issues as primary driversAlign Partners outlines measures for capital efficiency and governance normalization; requests a revised “Value-up” plan and a formal response from the Board by March 6, 2026The proposals nominate two Independent Directors via separate election and calls for the reinstatement of the Internal Transaction Committee Align Partners Capital Management Inc. (“Align Partners”), a shareholder of DB Insurance Co., Ltd. (KRX:005830) (“DBI” or the “Company”) holding 1.9%, has issued a public shareholder letter to DBI’s Board of Directors aimed at strengthening capital allocation policy and governance oversight, and submitted formal shareholder proposals for the 2026 Annual General Meeting (“AGM”). Despite DBI’s robust fundamentals—including a 16.1% ROE and a 226% K-ICS ratio—the Company trades at
Promega Unveils Cellular Target Engagement Technology Aimed at Expanding the Druggable Proteome at SLAS 20269.2.2026 13:00:00 CET | Press release
TarSeer™ BRETSA™ Target Engagement System enables studies for difficult proteins early in drug discovery Promega Corporation is launching a new live-cell target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins. The TarSeer™ BRETSA™ Target Engagement System is a novel bioluminescence resonance energy transfer-based shift assay for detecting ligand-protein interactions in intact cells using protein denaturation. It gives drug discovery researchers early, target-specific cellular insights by validating weak or early chemical matter and expanding the targets accessible in live-cell drug discovery workflows. The technology will be debuted at the Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in Boston, February 7-11, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260206015371/
Eurofins Viracor BioPharma Expands Bioanalytical Capabilities9.2.2026 13:00:00 CET | Press release
Eurofins Viracor BioPharma Services, a long‑standing and trusted partner for clinical trial testing solutions with deep expertise in specialty biomarkers and molecular assays, announces a significant expansion of its service portfolio with the addition of enhanced bioanalytical testing capabilities. These new services are fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), enabling the company to enhance support of biopharmaceutical development programs with greater scientific breadth throughout the drug development workflow. This strategic advancement follows the successful relocation and integration of Eurofins Pharma Bioanalytics Services from St. Charles, Missouri, into Eurofins Viracor BioPharma’s purpose‑built, eleven‑acre facility in Lenexa, Kansas. The bioanalytical organization brings more than two decades of specialized experience in pharmacokinetics, immunogenicity, and biomarker testing. By combining both laboratories’ strengths, Eurofins V
HKTDC to Host World’s Largest One-Stop Jewellery Marketplace9.2.2026 11:37:00 CET | Press release
New Hard Pure Gold Pavilion showcases breakthrough gold technologies Organised by the Hong Kong Trade Development Council (HKTDC), the world’s largest one‑stop jewellery marketplace will return in early March under its proven “Two Shows, Two Venues” format. The 12th Hong Kong International Diamond, Gem & Pearl Show will take place from 2 to 6 March at AsiaWorld‑Expo, featuring a wide range of jewellery raw materials. Also, the 42nd Hong Kong International Jewellery Show will be held from 4 to 8 March at the Hong Kong Convention and Exhibition Centre, showcasing finished jewellery pieces. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260207153040/en/ Hong Kong International Jewellery Show and Hong Kong International Diamond, Gem & Pearl Show Jenny Koo, Deputy Executive Director of the HKTDC, said: “This year’s twin jewellery shows bring together some 4,000 exhibitors from over 40 countries and regions, with nearly 70% coming
FlexTrade Integrates CME Group’s FX Spot+ and EBS Market Offerings for Enhanced FX Trading9.2.2026 11:30:00 CET | Press release
The initiative will see FlexTrade FX clients seamlessly access CME Group’s primary FX markets within FlexFX. FlexTrade Systems(@FlexTrade), a global leader in multi-asset execution and order management systems, today announced an integration with CME Group’s EBS Market central limit order book (CLOB) and its FX Spot+ platform.The move is designed to diversify and deepen the sources of actionable liquidity available to FlexTrade’s FlexFX users through an integration into CME Group's substantial liquidity pools for spots via FX Spot+. Providing firm, anonymous liquidity and no last-look pricing, EBS Market is a venue for both large market participants in search of FX liquidity in an all-to-all CLOB, and for market-making banks hedging FX risk. FX Spot+ further enhances spot liquidity with Futures liquidity from CME Group. This partnership is integral in helping firms further expand FX liquidity and take advantage of global opportunity. Mutual clients of FlexTrade and CME Group can integr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom